Sixty Degree Capital

Activity in this selectionBiotech

By stage

Series B2

Series A1

Series C+1

Biotech4

United States3

France1

4 in this selection

Jun 22

Developing next-generation biologics for severe immunological and inflammatory diseases

$165MSeries A

Role not disclosed

Mar 18

Develops a novel class of potent and precise antibody therapies to treat a broad range of cancers

$77MSeries B

Role not disclosed

Jan 10

Develops inhaled therapies for severe respiratory diseases

$103MSeries B

Role not disclosed

Jan 8

Develops medicines targeting historically undruggable protein targets in cancer

$305MSeries F

Role not disclosed